With the realization that GLP-1 and GIP were rapidly degraded in the circulation by DPP4, Carolyn Deacon and colleagues from the University of Copenhagen were quick to realize that inhibitors of the enzyme might represent a new therapeutic avenue to potentially treat T2D by enhancing incretin action [255]. Here, DPP4 is linked to type 2 diabetes mellitus.